Otezla (apremilast) — United Healthcare
Behçet’s disease
Initial criteria
- Diagnosis of Behçet’s disease
- Patient has oral ulcers attributed to Behçet’s disease
- Patient is not receiving Otezla in combination with another targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept), Simponi (golimumab), tocilizumab]
Reauthorization criteria
- Documentation of positive clinical response to Otezla therapy
- Patient is not receiving Otezla in combination with another targeted immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept), Olumiant (baricitinib), Orencia (abatacept), Simponi (golimumab), tocilizumab]
Approval duration
12 months